Patents by Inventor George Ayoub

George Ayoub has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240076316
    Abstract: Fusion Protein compositions comprising masked IFNs and methods of making masked IFNs are disclosed herein. Consequently, the masked IFNs can be fused to a Mab or binding fragment thereof and be administered to patients as a therapeutic modality and provide a method of treating cancer, immunological disorders and other disease.
    Type: Application
    Filed: September 14, 2023
    Publication date: March 7, 2024
    Applicant: Qwixel Therapeutics LLC
    Inventors: David STOVER, Sherie MORRISON, Alex VASUTHASAWAT, Kham TRINH, George AYOUB
  • Patent number: 11795198
    Abstract: Fusion Protein compositions comprising masked IFNs and methods of making masked IFNs are disclosed herein. Consequently, the masked IFNs can be fused to a Mab or binding fragment thereof and be administered to patients as a therapeutic modality and provide a method of treating cancer, immunological disorders and other disease.
    Type: Grant
    Filed: September 2, 2021
    Date of Patent: October 24, 2023
    Assignee: Qwixel Therapeutics LLC
    Inventors: David Stover, Sherie Morrison, Alex Vasuthasawat, Kham Trinh, George Ayoub
  • Patent number: 11763387
    Abstract: The system and methodology of the present invention operate, in one embodiment, to provide a set of cloud-based applications through which creators, initial investors and secondary investors can all interact so that content catalogs can be valued, initially invested in and traded on a secondary basis. As a result, content creators can source valuable capital for growth and expansion as well as other purposes. Separately, the system and methodologies of the present invention provide the unique opportunity for investors to invest in an interesting asset class which is diverse from other typical investment vehicles. The ability to rely on automated valuations at the time of the initial offering as well as the liquidity provided via secondary trading enhances the desirability of the content catalog asset class as well as the revenue streams associated therewith.
    Type: Grant
    Filed: February 3, 2023
    Date of Patent: September 19, 2023
    Assignee: Sharematter Inc.
    Inventors: Georges Ayoub, Zeid Ayoub
  • Publication number: 20230263802
    Abstract: Methods of reducing incidence of or risk of developing a cerebral folate deficiency (CFD) or a CFD-related disorder comprising administering reduced folate compounds.
    Type: Application
    Filed: July 27, 2021
    Publication date: August 24, 2023
    Inventors: George Ayoub, Dominic Man-Kit Lam
  • Publication number: 20220056076
    Abstract: Fusion Protein compositions comprising masked IFNs and methods of making masked IFNs are disclosed herein. Consequently, the masked IFNs can be fused to a Mab or binding fragment thereof and be administered to patients as a therapeutic modality and provide a method of treating cancer, immunological disorders and other disease.
    Type: Application
    Filed: September 2, 2021
    Publication date: February 24, 2022
    Applicant: Qwixel Therapeutics LLC
    Inventors: David STOVER, Sherie MORRISON, Alex VASUTHASAWAT, Kham TRINH, George AYOUB
  • Patent number: 11136353
    Abstract: Fusion Protein compositions comprising masked IFNs and methods of making masked IFNs are disclosed herein. Consequently, the masked IFNs can be fused to a Mab or binding fragment thereof and be administered to patients as a therapeutic modality and provide a method of treating cancer, immunological disorders and other disease.
    Type: Grant
    Filed: April 15, 2020
    Date of Patent: October 5, 2021
    Assignee: Qwixel Therapeutics LLC
    Inventors: David Stover, Sherie Morrison, Alex Vasuthasawat, Kham Trinh, George Ayoub
  • Publication number: 20200331966
    Abstract: Fusion Protein compositions comprising masked IFNs and methods of making masked IFNs are disclosed herein. Consequently, the masked IFNs can be fused to a Mab or binding fragment thereof and be administered to patients as a therapeutic modality and provide a method of treating cancer, immunological disorders and other disease.
    Type: Application
    Filed: April 15, 2020
    Publication date: October 22, 2020
    Applicant: Qwixel Therapeutics
    Inventors: David STOVER, Sherie MORRISON, Alex VASUTHASAWAT, Kham TRINH, George AYOUB
  • Publication number: 20080026073
    Abstract: Treatment of glutamate toxicity is accomplished using Lithium or a composition of Lithium and a botanical extract. The composition is administered using conventional techniques to increase the survival of ganglion cells exposed to glutamate toxicity resulting from ischemic events. In exemplary embodiments, the botanical extract is St. Johns Wort, Tian Qi or Dong Gui.
    Type: Application
    Filed: June 29, 2007
    Publication date: January 31, 2008
    Inventors: William Peitzke, George Ayoub